Experimental drug targets leukemia and lymphoma in early trial
NCT ID NCT00081874
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This study tested a drug called RAD001 (everolimus) in 29 people with blood cancers like leukemia, lymphoma, or myelofibrosis that had come back or not responded to treatment. The goal was to find the safest dose and see if it could shrink or control the cancer. The trial combined early safety testing (Phase I) with a first look at effectiveness (Phase II).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M.D. Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
RAD001 (everolimus, Afinitor)
What this could lead to
If it works, this could point toward a treatment option for certain blood cancers that have not responded to standard therapy.
What could go wrong
This is an early-phase trial with only 29 participants, so results may not apply broadly. The drug may cause side effects or fail to control the disease.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.